The TILs represent pre-existing anti-tumor immunity, with prognostic relevance and predictive value in BC, especially for HER2+ and triple negative breast cancers (110, 111), although the BC has not classically been considered as an immunogenic neoplasm. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.